HOOKIPA PharmaHOOK 49 FCF Margin % is -104.97% as of Jun. 2025. GuruFocus rates HOOK with a GF Score™ of 49/100 and a GF Value™ of $2.78 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 960 Biotechnology companies, HOOKIPA Pharma ranks worse than 65.21% on this metric.
The historical rank and industry rank for HOOKIPA Pharma's FCF Margin % or its related term are showing as below:
HOOK'
s FCF Margin % Range Over the Past 10 Years
Min: -426.05 Med: -224.77 Max: -175.55
Current: -306.81
During the past 8 years, the highest FCF Margin % of HOOKIPA Pharma was -175.55%. The lowest was -426.05%. And the median was -224.77%.
HOOK's FCF Margin % is ranked worse than 65.21% of 960
companies
in the Biotechnology industry
Industry Median: -85.21
vs HOOK: -306.81
HOOKIPA Pharma FCF Margin % Related Terms
HOOKIPA Pharma FCF Margin % Historical Data
* Premium members only.
The historical data trend for HOOKIPA Pharma's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, HOOKIPA Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HOOKIPA Pharma FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HOOKIPA Pharma's FCF Margin % distribution charts can be found below:
* The bar in red indicates where HOOKIPA Pharma's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOOKIPA Pharma (HOOK) has a FCF Margin % of -104.97% as of Jun. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on HOOKIPA Pharma and its competitors. According to the industry distribution chart, HOOKIPA Pharma ranks #626 out of 960 companies in the Biotechnology industry, placing it in the top 65.2%.
Is HOOKIPA Pharma's FCF Margin % too high?
HOOKIPA Pharma's current FCF Margin % is -104.97%. Based on the distribution chart, HOOKIPA Pharma ranks #626 out of 960 companies in the Biotechnology industry, which is below the industry midpoint. Overall, HOOKIPA Pharma has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HOOKIPA Pharma's FCF Margin % compare to LNAI and ZEOX?
According to the Biotechnology industry distribution chart, HOOKIPA Pharma ranks #626 out of 960 companies for FCF Margin %. This places HOOKIPA Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on HOOKIPA Pharma and its competitors. HOOKIPA Pharma's current FCF Margin % is -104.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOOKIPA Pharma stock overvalued right now?
Based on GuruFocus' analysis, HOOKIPA Pharma (HOOK) is currently considered Possible Value Trap. The stock's GF Value™ is $2.78, compared to a current price of $1.15 — trading 58.6% below its estimated fair value. The current FCF Margin % is -104.97%. HOOKIPA Pharma's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For HOOKIPA Pharma (HOOK), the current FCF Margin % is -104.97% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HOOKIPA Pharma (HOOK) Overvalued in 2026?
Based on GuruFocus' analysis, HOOKIPA Pharma stock appears to be undervalued.
The current stock price of $1.15 is trading 58.6% below its estimated GF Value™ of $2.78.
GuruFocus considers HOOKIPA Pharma to be Possible Value Trap.
Key valuation signals for HOOK:
FCF Margin %: -104.97%
GF Value™: $2.78 vs. price of $1.15 (58.6% below fair value)
No single metric tells the full story. See the HOOK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company's product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. In addition, It is also focused to develop therapies that are intended to provide functional cures for hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).
49GF Score
Get the complete analysis for HOOK
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HOOK has been successfully added to your 
